|Awarded On||August 21, 2019|
|Title||Tumor specific T-cell activating cancer vaccines for immunotherapy of solid tumors including HPV|
|Program||Product Development Research|
|Award Mechanism||Texas Company Product Development Awards|
|Principal Investigator/Program Director||Ravi Srinivasan|
|Cancer Sites||Cervix Uteri, Head and Neck, Penis|
*Pending contract negotiation
OncoNano Medicine, Inc., a spinout of UT Southwestern that is headquartered in Southlake, TX, is developing a nanovaccine immunotherapeutic for human papilloma virus (HPV)-induced cervical cancer, head and neck cancer, and anogenital cancers. OncoNano’s technology is a proprietary, polymer-based, pH-sensitive micelle that delivers an antigen to the lymph nodes, while also activating the stimulator of interferon genes (STING) pathway, resulting in a cancer-specific patient immune response. Cervical cancer is one of the leading causes of cancer mortality among women, and more than 270,000 deaths occur from cervical cancer each year worldwide. With this urgent need, OncoNano’s unique approach t...